IRIS
AZZONI, Cinzia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.666
AS - Asia 2.020
EU - Europa 1.694
SA - Sud America 316
AF - Africa 109
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.582
SG - Singapore 800
CN - Cina 731
IE - Irlanda 318
IT - Italia 278
SE - Svezia 264
FI - Finlandia 243
BR - Brasile 242
HK - Hong Kong 166
DE - Germania 144
VN - Vietnam 129
UA - Ucraina 101
ZA - Sudafrica 72
NL - Olanda 69
GB - Regno Unito 64
TR - Turchia 60
CA - Canada 57
AT - Austria 49
RU - Federazione Russa 47
IN - India 37
AR - Argentina 35
FR - Francia 33
BE - Belgio 24
BD - Bangladesh 18
PL - Polonia 18
MX - Messico 17
EC - Ecuador 14
ES - Italia 14
IQ - Iraq 12
CI - Costa d'Avorio 10
JP - Giappone 10
MA - Marocco 9
CZ - Repubblica Ceca 7
ID - Indonesia 7
LT - Lituania 7
UZ - Uzbekistan 7
IR - Iran 6
PE - Perù 6
PK - Pakistan 6
VE - Venezuela 6
DZ - Algeria 5
KE - Kenya 5
KR - Corea 5
CL - Cile 4
JO - Giordania 4
AU - Australia 3
BH - Bahrain 3
BO - Bolivia 3
EG - Egitto 3
PA - Panama 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
OM - Oman 2
PY - Paraguay 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.810
Salva come PNG Salva come JPEG
Città #
Singapore 452
Ashburn 386
Chandler 357
Dublin 318
Santa Clara 199
Hong Kong 165
Beijing 155
Dallas 153
Jacksonville 110
Dearborn 105
Boardman 95
Parma 95
Ann Arbor 92
Los Angeles 82
Shanghai 80
New York 78
Nanjing 70
Johannesburg 66
Ho Chi Minh City 49
Princeton 48
Vienna 46
Izmir 43
Munich 40
Hefei 37
Jinan 37
Helsinki 34
Hanoi 30
Turku 30
Wilmington 30
Shenyang 28
San Mateo 27
São Paulo 27
Tianjin 25
Toronto 24
Moscow 21
Seattle 21
Bologna 19
Columbus 19
Nanchang 19
Bremen 18
Brussels 18
Chicago 18
Changsha 17
Hebei 17
Buffalo 16
Marseille 16
Woodbridge 16
Kunming 14
Pune 14
Warsaw 14
Guangzhou 13
Montreal 12
Ankara 11
Denver 11
Des Moines 11
Hangzhou 11
London 11
Nuremberg 11
Abidjan 10
Rio de Janeiro 10
The Dalles 10
Tokyo 10
Atlanta 9
Brooklyn 9
Manchester 9
Redondo Beach 9
Frankfurt am Main 8
Haikou 8
Phoenix 8
Poplar 8
Rio Saliceto 8
San Francisco 8
Stockholm 8
Taiyuan 8
Zhengzhou 8
Council Bluffs 7
Ningbo 7
Orem 7
Ottawa 7
Baghdad 6
Castrezzato 6
Chennai 6
Jiaxing 6
Louvain-la-Neuve 6
Modena 6
Norwalk 6
Amsterdam 5
Biên Hòa 5
City of London 5
Houston 5
Jakarta 5
Lanzhou 5
Lima 5
Nairobi 5
Seoul 5
Taizhou 5
Tashkent 5
Amman 4
Auburn Hills 4
Borås 4
Totale 4.266
Salva come PNG Salva come JPEG
Nome #
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 174
Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors 160
High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer 154
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 153
Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? 149
Human Papilloma Virus (HPV) status, P16INK4a and p53 overexpression in epithelial malignant and borderline ovarian neoplasms 145
Classification of gastric endocrine cells at the light and electron microscopical levels 144
P-027Cancer stem cells marker CD44 and Notch activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapy 142
Notch expression and bevacizumab efficacy in colorectal cancer patients 141
ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis 140
Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract 140
Histological subtype analysis of colon cancer: a population-based study. Different sides and different diseases. 140
Atrophic body gastriris patients with enterochromaffin-like cell dysplasia are at increased risk for development of type I gastric carcinoid 139
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer 139
ANASTOMOTIC RECURRENCE OF COLON CANCER: GENETIC ANALYSIS CHALLANGES THE WIDELY HELD THEORIES OF CANCEROUS CELLS’ INTRALUMINAL IMPLANTATION AND METACHRONOUS CARCINOGENESIS 137
Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series 137
Cancer stem cells related marker CD44 and Notch activation in metastatic colon cancer patients 135
REPEATED ANASTOMOTIC RECURRENCE OF COLORECTAL TUMORS. GENETIC ANALYSIS OF TWO CASES. 133
Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas 131
Different patterns of 11q allelic losses in digestive endocrine tumors 127
p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior 126
Pleomorph poorly differentiated endocrine carcinoma of the rectum 125
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 124
Notch Activation Modulates Bevacizumab Activity by CD44 Positive Cancer Stem Cells in Advanced Colon Cancer 124
Malignancy-associated allelic losses on X chromosome in foregut but not in midgut endocrine tumours 123
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 121
The antral mucosa as a new site for endocrine tumors in Multiple Endocrine Neoplasia type-1 and Zollinger Ellison syndromes 121
Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. 120
Adenomatous polyposis coli gene involvement in ileal enterochromaffin cell neuroendocrine neoplasms. 120
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 119
Pancreatic Polypeptide-related tumors 118
Metaplastic papillary tumour of the salpinx: report of a case with microsatellite analysis 118
Microsatellite instability in colorectal cancer 117
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 117
Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1. 116
Primary Squamous Cell Carcinoma of the Endometrium Unrelated to Human Papilloma Virus: A Molecular Study 115
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 114
Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy 112
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer 109
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin 109
Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features 108
Sporadic colorectal carcinomas with low-level microsatellite instability: a distinct subgroup with specific clinicopathological and molecular features. 108
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 108
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 106
REPEATED ANASTOMOTIC RECURRENCE OF COLORECTAL TUMORS. GENETIC ANALYSIS OF TWO CASES. 102
P16INK4a overexpression independent of Human Papilloma Virus (HPV) infection in rare subtypes of endometrial carcinomas 98
Surgical treatment of multiple sporadic colorectal carcinoma 97
Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome 91
Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients 88
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. 87
Genetics of Darier’s Disease: New Insights into Pathogenic Mechanisms 82
Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort 77
Impact of preoperative chemoradiotherapy on tumor infiltrating lymphocytes in locally advanced rectal cancer: The SMART-STAR study 70
Sampling strategies for analysis of enterochromaffin-like (ECL) cell changes in Zollinger-Ellison syndrome 69
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 68
Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort 67
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 59
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 56
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature 50
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 42
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 28
Totale 6.889
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.435
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.435
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021134 0 0 0 0 0 8 25 10 48 7 32 4
2021/2022279 6 1 4 18 13 8 42 24 16 17 34 96
2022/20231.232 106 155 66 96 101 146 12 85 393 14 43 15
2023/2024435 27 29 9 7 30 121 42 41 17 24 25 63
2024/20251.433 36 65 97 104 175 182 74 50 162 108 119 261
2025/20262.101 335 248 414 460 565 79 0 0 0 0 0 0
Totale 6.889